Silvia Antolín

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 580 citations · Full text

Breast Oncology, Medicine, Clinical Trials +8

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer, Amylou C. Dueck, Miguel Martín et al. · The Lancet Oncology · 2021 · 250 citations

Interim Analysis, Endocrine Oncology, Breast Oncology +9

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván et al. · Cancer Research · 2017 · 239 citations · Full text

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Ángela Santonja, Alfonso Sánchez‐Muñoz, Aňa Lluch et al. · Oncotarget · 2018 · 182 citations · Full text

Lehmann Tnbc Subtypes, Breast Oncology, Tumor Heterogeneity +13

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study

Adela Castelló, Marina Pollán, Brian Buijsse et al. · British Journal of Cancer · 2014 · 179 citations · Full text